Chapter 287
Chapter 287
Seraphine didn't offer excuses—each frame of data answered the accusations.
The investigation team went from skeptical to stunned.
The lead expert studied a complex algorithm model. "Dr. Manners, this neural signal redundancy error-correction algorithm—was it inspired by string theory?"
"Yes."
The expert turned to his team. "Pack it up. If this product is flawed, then ninety-nine percent of the world's drugs should be pulled from shelves."
The truth was laid bare.
After the investigation team left, John felt completely drained.
Watching Seraphine's retreating figure, he realized that any business tactic was infantile compared to her absolute scientific prowess.
Just as Nolan & Heidi Medical Research Center prepared to release a clarification announcement, the Talbot Group's official website posted a statement in bold black text at the very top.
[The Talbot Group expresses unreserved trust and support for Nolan & Heidi Medical Research Center and the G17 compound. G17-related technology has been deeply integrated into multiple core classified Talbot Group projects. Regarding this anonymous defamation, our legal department has partnered with national security forces to launch a source investigation. Any attack on Nolan & Heidi Medical Research Center will be considered a direct provocation against the Talbot Group. We will deploy all resources to pursue accountability to the fullest extent.]
This went far beyond a business endorsement.
Ten minutes after the statement posted, Nolan & Heidi Medical Research Center and its affiliated companies' stocks rebounded from a brief dip, driven by massive capital inflows, hitting the daily limit across the board.
That evening, in the apartment.
Seraphine finished her work and saw Lucius standing before the information terminal.
The screen displayed locked offshore IP addresses and fund flow patterns.
He turned, pushing a glass of warm water toward Seraphine.
"Novarex Pharma's executive director has been removed by the board." His tone was flat.
Seraphine took the water glass without thanking him.
She studied his profile against the night view and said softly, "The orca's genetic sequence is mapped. More complex than expected, but also more interesting."
...
A month later, in Seraphine's apartment, Lucius's team vanished as efficiently and silently as they'd arrived, leaving only sunlight filling the room.
A biosignal collection device now sat on the living room coffee table.
John arrived with documents for signing and found Seraphine attaching sensor patches to her recovering right arm.
Her movements were slow, but she no longer required the support sling.
"Ms. Manners, what are you..."
Seraphine focused intently on the tablet.
On screen, as her arm lifted slightly, data streams jumped, generating a three-dimensional musculoskeletal model.
A diagnostic conclusion appeared: [Right supraspinatus muscle strength recovery 87%, nerve conduction velocity improved 12% compared to pre-surgery. Recommend increasing resistance rotation training.]
John's eyes widened. "Is this that medical AI platform? 'Aurora'?"
"Final internal testing version." Seraphine removed the patches and moved her shoulder. The data refreshed again.
John pointed at a corner of the screen. "Why is there a health report on me?"
A small window displayed: [Target individual exhibits elevated heart rate, cortisol levels above normal threshold. Assessment indicates a chronic high-pressure anxiety state with mild fatty liver. Recommendations: reduce red meat intake, increase aerobic exercise.]
John's face flushed. "How does it know I had BBQ pork ribs twice last week?!"
"Aurora's passive environmental monitoring function." Seraphine's tone was calm. "As long as it's running, sensors perform baseline scans on any biological entities entering range. Your file was created on your first visit."
A chill ran down John's spine.
Seraphine closed the interface and handed him the tablet. "It doesn't steal jobs—it just puts the most precise scalpel in the doctor's hands."
Lucius called then.
"Results in?"
"Exceeded projections."
"Press conference is set for next Wednesday. All Talbot Group medical institutions will be first-wave users, with full Aurora system integration."
Next Wednesday, Skyview City International Convention Center.
Nolan & Heidi Medical Research Center's Aurora AI platform launch drew global attention.
The venue was packed.
John was a nervous wreck backstage.
He watched Seraphine walk onto the stage alone in a white suit, her right arm moving freely, her entire presence calm and powerful.
She skipped emotional openings and went straight to demonstrating Aurora's capabilities—from gene sequencing analysis to rare disease diagnostic assistance to drug development simulation.
Gasps of amazement rippled through the audience.
This wasn't simple medical software—it was an ecosystem-level platform capable of revolutionizing the industry.
Just as Seraphine prepared the final demonstration, the venue's rear doors opened.
The hall's buzz froze.
Lucius appeared at the entrance, but even more breathtaking was who followed him: the entire Talbot Group board of directors and top executives from each core business division.
They wore solemn expressions, walking with measured steps to the reserved first-row seats. The formation didn't look like attending a launch—it looked like reviewing troops.
Camera flashes went wild.
The entire industry knew about the partnership between the Talbot Group and Nolan & Heidi Medical, but they'd never witnessed support at this level.
This transcended support—it was crowning Seraphine with the entire Talbot Group empire's reputation.
Onstage, Seraphine merely glanced over calmly, then continued her demonstration as if this earth-shattering scene meant nothing.
Backstage, John's legs went weak. The PR director had to pinch her pressure point to keep from fainting.
After the launch, guests moved to the reception area.
The moment Seraphine came offstage, Lucius intercepted her.
He offered no congratulations, only extended his personal tablet.
The screen showed a data report: [Comprehensive Benefit Assessment of Aurora System Trial Operation at Three Talbot Group Subsidiary Hospitals].
The report showed that over the past month, these three hospitals, which were secretly running Aurora's beta version, had seen significant optimization in core metrics like outpatient misdiagnosis rates, surgical planning time, and bed turnover rates.
At the report's end, a bold red number summarized everything:
[Overall operational efficiency improvement: 40%]
Everyone understood.
Aurora 2.0 wasn't just a product iteration—it was a dimensional leap.
John's mouth hung open, speechless.
He finally grasped the meaning of Seraphine's words—while others were still imitating abacuses, they'd already produced a supercomputer.
"Um... Ms. Manners," a young engineer stammered, "with such powerful features, when's the next launch?"
"There isn't one." Seraphine closed the screen. "Next Monday, direct online push update. All 1.0 users get free upgrades."
Free?
John's vision went black.
This wasn't just pulling the rug out—it was directly eliminating competitors along with their entire market.
Friday afternoon, at a Talbot Group top-level strategy meeting, Barry was reporting market analysis on Morningstar Tech and the Origin system.
Lucius interrupted. "Not necessary."
He gazed out the window. "Barry, send notice through all channels."
"First, all Talbot Group medical, wellness, and insurance institutions immediately and permanently terminate all cooperation with the Origin system. Existing contracts to be canceled immediately—the Group covers penalty fees."
"Second, after Aurora 2.0 launches Monday, all relevant business lines must complete full deployment within seventy-two hours. I want efficiency optimization reports at Thursday morning's meeting."
"Third," he turned to the marketing director, "launch a trade-in program. Any medical institution that purchased Origin can receive double their purchase amount in special subsidies when buying Aurora 2.0 upon presenting their contract."